Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
about
Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complicationPharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular DiseaseTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.Diabetic kidney disease: from physiology to therapeuticsDiabetic Kidney Disease: Pathophysiology and Therapeutic TargetsPimagedine: a novel therapy for diabetic nephropathy.Evolving pandemic diabetic nephropathyDiabetic macular edema: classification, medical and laser therapy.Current and future pharmacological intervention for diabetic retinopathy.Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapyEllagic acid, a new antiglycating agent: its inhibition of Nϵ-(carboxymethyl)lysine.Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats.The accuracy of digital-video retinal imaging to screen for diabetic retinopathy: an analysis of two digital-video retinal imaging systems using standard stereoscopic seven-field photography and dilated clinical examination as reference standards.Methylglyoxal scavengers attenuate endothelial dysfunction induced by methylglyoxal and high concentrations of glucose.Protein kinase C and the development of diabetic vascular complications.Mesona Chinensis Benth extract prevents AGE formation and protein oxidation against fructose-induced protein glycation in vitro.Age-related vascular stiffening: causes and consequences.Novel therapeutic strategies for reducing arterial stiffnessEmerging drugs for renal failure.Systems biology of kidney diseases.Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease.Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.Inhibitory effect of herbal medicines and their trapping abilities against methylglyoxal-derived advanced glycation end-products.Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.Protective Effects of Corni Fructus against Advanced Glycation Endproducts and Radical Scavenging.Cyanidin-3-rutinoside attenuates methylglyoxal-induced protein glycation and DNA damage via carbonyl trapping ability and scavenging reactive oxygen species.Aminoguanidine prevents fructose-induced deterioration in left ventricular-arterial coupling in Wistar rats.Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?Prevention of advanced glycation end-products formation in diabetic rats through beta-cell modulation by Aegle marmelosRedox control of renal function and hypertension.Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications.Inhibition of advanced glycation endproduct formation by foodstuffs.Naturally occurring inhibitors against the formation of advanced glycation end-products.Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward.Current therapeutic interventions in the glycation pathway: evidence from clinical studies.Therapeutic potential of targeting lipid aldehydes and lipoxidation end-products in the treatment of ocular disease.Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.Semicarbazide-sensitive amine oxidase and kidney disease.The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases.
P2860
Q26751110-55D2D583-FB51-4570-A5C1-337ECE715EF2Q26782422-F5F42A4F-C011-452B-A2E0-89CF04700CDFQ27007027-657A523C-04C2-4070-A28E-24D55715E371Q27021392-F3412170-B145-4AFA-8F35-6170FBB67629Q28086840-0CBFFF62-C19F-44A7-A9E1-E1D9BBA8153BQ30309168-E69FC34E-C66D-4CB9-A1AC-56D841EAC919Q30352538-2FE9B154-3C90-444A-AB28-E13C542299EFQ33208471-C69AFC26-A2E9-452F-9431-8E912E88B384Q33216425-F7DFDED0-807D-4B9B-9C42-13A863F55F45Q33807824-7F26D180-B24C-4922-9BB4-4727C0797F2FQ34068791-66A521B1-64C6-451D-A9AA-069A7C8702BBQ34079319-55B2DA4B-E936-4C9D-AE50-CF9E373EDCC3Q34123557-A95D3689-8BED-4903-926C-39043F685EE8Q34442434-1C45F177-E573-4943-9A2C-56E2FC8E30BCQ34570516-136353D4-4CB3-48E0-BE24-77B111693729Q35141196-F985ACA0-EFC2-49B6-9649-D01B447BA0DDQ35409645-D72BB586-E3A3-4420-A50E-1E2D4B4113C0Q35546271-C2E04CDC-B404-4F6D-AE2A-D0C7C7FDCC6BQ35602657-2C66E4F9-F3FB-44A4-998F-3051F54EC9A4Q35619034-C9F64C69-48DB-441A-AD13-C01C680F45ADQ35796793-2179ACC0-12CD-482C-97F8-26F74B9E085EQ35809946-90590122-F2F0-4F9E-82BF-11FBE89EC668Q35828446-3B1ADCBA-81B6-4B2D-92C2-6C1B74F29D1AQ35896615-8D836656-CE0F-49B8-A061-6C533F13932DQ35977602-2F1CE5A3-1723-4075-960C-438D4978DE5EQ36026951-5EE5B607-407C-4987-A0D3-1952A6AD518FQ36052796-D5AB0551-2827-495F-8CE7-F190748A9428Q36293649-9508B416-6FA0-439A-B60B-C21291989E74Q36353847-6E760C53-EFF4-4AE2-95C7-4F56A2B89ABFQ36970633-5BAAEF9C-B962-41A9-962A-A5CBE303CF58Q37058905-23DEB7D1-B476-4F9C-AE14-0B747F8F7317Q37903707-AC447E04-41BA-459B-A7A7-D23DA4BAC32CQ37903708-E06424AE-51F6-4E32-A7CA-1A39F9B2C49DQ37959165-2B8C03EF-4CF9-43A9-9029-BEA0D26BB396Q38070906-3FA76B06-C6A7-4B17-BBC9-F9F014D994D1Q38077549-71760A61-F321-4350-B50E-33F8A5CA393DQ38096444-3365011A-E294-4921-9C8D-8053F52AE621Q38156644-F09122A8-BBD8-413A-AB98-D90E19C2D459Q38241689-04A4F8B0-21C5-4134-BE23-6A08380B4947Q38394355-DD0EF491-4763-4206-8DC6-BD1DE38B14F6
P2860
Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Design and baseline characteri ...... betic Nephropathy (ACTION II).
@en
Design and baseline characteri ...... rt Type 2 Diabetic Nephropathy
@nl
type
label
Design and baseline characteri ...... betic Nephropathy (ACTION II).
@en
Design and baseline characteri ...... rt Type 2 Diabetic Nephropathy
@nl
prefLabel
Design and baseline characteri ...... betic Nephropathy (ACTION II).
@en
Design and baseline characteri ...... rt Type 2 Diabetic Nephropathy
@nl
P2093
P1476
Design and baseline characteri ...... betic Nephropathy (ACTION II).
@en
P2093
Cartwright K
Freedman BI
Mooradian AD
Spinowitz BS
P304
P356
10.1016/S0197-2456(99)00024-0
P407
P577
1999-10-01T00:00:00Z